Ruxolitinib is an anticancer drug and a Tyrosine Protein Kinase JAK1 and JAK2 Inhibitor. It is the first JAK inhibitor approved by the FDA to treat patients with advanced stages of myelofibrosis and polycythemia vera (PV).
The drug-treated population of atopic dermatitis may grow to 24 million and market is expected to grow to $18.3B by 2027.
| Product Name |
Ruxolitinib Phosphate |
| CAS Number |
1092939-17-7 |
| Therapeutic Class |
Antineoplastic Agents, Antirheumatic Agents, JAK Inhibitors |
| Dosage Form |
Oral Tablet, Topical |
| Availability |
Under Evaluation |
| Regulatory Status |
|